Live Breaking News & Updates on Kite Pharmaceuticals|Page 4
Stay updated with breaking news from Kite pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chimeric Therapeutics Ltd non-executive director shows confidence in bio-tech strategy with on-market purchase proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics’ pipeline with additional novel cell therapies. ....
In the fall of 2016, Alnylam Pharmaceuticals was looking to expand. The Cambridge, Massachusetts–based company had therapies based on RNA interference (RNAi) technology in late-stage clinical testing for a handful of rare diseases, and wanted to establish a presence in Europe to better serve patients there. By the end of the following year, the company had opened offices in Maidenhead, UK; Zug, Switzerland; and Amsterdam, the Netherlands, to serve as its three European hubs. Scouting for new locations in Europe, the company found Amsterdam particularly appealing, says Marco Fossatelli, Alnylam’s country manager in the Netherlands. Alnylam already had long-standing partnerships with three large academic medical centers in the Netherlands that had hosted some of the company’s Phase 3 trials. And Amsterdam checked all the right boxes: it has a highly skilled workforce and is easily accessible and navigable by public transportation. It also had a blossoming life sciences and ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer NexImmune, Inc.January 18, 2021 GMT With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy programs GAITHERSBURG, Md., Jan. 18, 2021 (GLOBE NEWSWIRE) NexImmune today announced the appointment of Dr. Robert (Bob) Knight as Chief Medical Officer (CMO). Dr. Knight is a seasoned executive with extensive experience leading early- and late-stage immunotherapy product development teams. Prior to joining NexImmune, Dr. Knight led the Yescarta® clinical program at Kite Pharmaceuticals (a Gilead Company) and, prior to that, spent 16 years at Celgene Corporation as a Vice President in Clinical Research. During his tenure at Celgene, he helped le ....